

# Understanding the Burden of Illness in People with Nonrelapsing Secondary Progressive Multiple Sclerosis in the United States: A Matched-cohort Study

Nupur Greene<sup>1</sup>, Ashis K. Das<sup>2</sup>, Ines Hemim<sup>1</sup>, Eunice Chang<sup>2</sup>, Marian H. Tarbox<sup>2</sup>, Keiko Higuchi<sup>3</sup>

<sup>1</sup>Sanofi, Cambridge, MA, USA; <sup>2</sup>PHAR, Beverly Hills, CA, USA; <sup>3</sup>Sanofi, Bridgewater, NJ, USA

## BACKGROUND

- Multiple sclerosis (MS) is categorized into relapsing or progressive forms based on its clinical course<sup>1</sup>
  - Relapsing-remitting MS (RRMS) is the most common form of MS representing around 85% of the total MS cases<sup>1</sup>
  - Approximately 50% of people with RRMS progress to secondary progressive MS (SPMS) over 10–15 years<sup>2,3</sup>
  - However, many people with SPMS continue to accumulate disability in the absence of clinical relapses and can be termed as nonrelapsing SPMS (nrSPMS)
- Although several disease-modifying therapies (DMTs) are available for relapsing MS in the United States (US), there are no DMTs approved for nrSPMS<sup>4</sup>
- While it is known that people with MS have a substantially lower quality of life and higher healthcare costs (HCCs) than the general population,<sup>5,6</sup> data on the clinical and economic burden in people with nrSPMS are lacking

## OBJECTIVE


To understand the real-world clinical and economic burden in people with nrSPMS in the US

## METHODS

### Study design

- A retrospective, matched-cohort study was conducted using the Optum Market Clarity linked EHR and claims database, i.e. a large, integrated US-based administrative health database from 01/01/2012 to 12/31/2021 (Figure 1)
- People with nrSPMS were matched to unique MS-free controls based on age, sex, race, region, and insurance (1:1). The index date of control was the same as matched MS patients

Figure 1: Study time frame



### Study population

- The nrSPMS cohort consisted of people with MS who had an SPMS electronic health record (EHR) during the identification period (Figure 1)
  - An additional continuous enrollment during a 2-year baseline period was required to classify people with SPMS into nrSPMS (defined as no relapse in prior 2 years) and active SPMS (defined as ≥1 relapse in prior 2 years)
- The identification of the nrSPMS cohort was also carried out using a validated claim-based nrSPMS algorithm<sup>7</sup>
  - People were excluded if they were aged >70 years, OR had a primary diagnosis of other neurological disorder (Alzheimer's, Parkinson's disease, myasthenia gravis, or stroke), OR had evidence of relapse during the 2-year baseline period

### Study measures

- Demographics, Charlson Comorbidity Index (CCI), specific comorbidities of interest, healthcare resource utilization (HCRU), and HCCs were compared with the controls during the 1-year follow-up period
  - HCRU and HCCs included inpatient admissions, emergency room visits, outpatient services, pharmacy costs, use of specific services, and cost of infections
- Treatment patterns were observed for people with MS during the 1-year follow-up period

### Statistical analysis

- Descriptive statistical analyses were used to compare all study measures
- All costs were reported in US dollars (adjusted to Year 2021)
- All tests were 2-sided, and  $P < 0.05$  was considered significant


**Disclosures**  
Nupur Greene, Ines Hemim, and Keiko Higuchi: Employees of Sanofi and may hold stocks or stock options in the company. Ashis K. Das, Eunice Chang, and Marian H. Tarbox: Employees of PHAR, which was paid by Sanofi to conduct the research described in this poster. PHAR also discloses financial relationships with the following commercial entities outside of the submitted work: Accea, Amgen, Celgene, Delfi Diagnostics, Dompé, Exact Sciences Corporation, Genentech, Gilead, GRAIL, Greenwich Biosciences, Ionis, Nobelpharma, Novartis, Pardes, Prothena, Pfizer, Recordati, Regeneron, Sanofi US Services, and Sunovion.

## RESULTS

### Demographics

- A total of 858 people with nrSPMS were identified, out of which 856 were included in the final cohort (Figure 2) along with the 856 matched MS-free controls. Two people with nrSPMS were excluded as they had no matched controls

Figure 2: Attrition chart for nrSPMS cohort



- The mean (standard deviation [SD]) age of the nrSPMS cohort was 54.4 (10.7) years; majority were female (79.8%) and Caucasian (87%; Table 1)

Table 1: Demographics of people in the nrSPMS cohort versus controls

Variable	nrSPMS cohort (N = 856)	Control cohort (N = 856)
Age (years), mean ± SD	54.4 ± 10.7	54.4 ± 10.7
18–34	43 (5.0)	43 (5.0)
35–54	343 (40.1)	343 (40.1)
55–64	312 (36.4)	312 (36.4)
65+	158 (18.5)	158 (18.5)
Female	683 (79.8)	683 (79.8)
Race		
Caucasian	745 (87.0)	745 (87.0)
African American	63 (7.4)	63 (7.4)
Other/Unknown	48 (5.6)	48 (5.6)
Region		
Midwest	398 (46.5)	398 (46.5)
Northeast	180 (21.0)	180 (21.0)
South	109 (12.7)	109 (12.7)
West	140 (16.4)	140 (16.4)
Other/Unknown	29 (3.4)	29 (3.4)
Plan type		
Commercial	442 (51.6)	442 (51.6)
Medicaid	26 (3.0)	26 (3.0)
Medicare	324 (37.9)	324 (37.9)
Unknown	64 (7.5)	64 (7.5)

Data presented as n (%) unless otherwise specified. nrSPMS, nonrelapsing progressive multiple sclerosis; SD, standard deviation.

### Medical writings

Medical writing and editorial assistance were provided by Shreya Dam and Chiranjit Ghosh, PhD of Sanofi.


### Funding

This study was sponsored by Sanofi.

### Clinical characteristics

- The mean CCI score was significantly lower in the nrSPMS cohort than that in matched controls (1.02 vs. 1.21;  $P = 0.032$ )
- A higher proportion of people in the nrSPMS cohort reported infections and leukopenia compared with matched controls (Figure 3)

Figure 3: Proportion of people with infections and leukopenia in the nrSPMS cohort versus matched controls




Data presented as the percentage of people with nrSPMS. nrSPMS, nonrelapsing secondary progressive multiple sclerosis; NS, non-significant.

### Specific comorbidities of interest

- The top five most frequent MS-related comorbidities in people with nrSPMS vs. controls included malaise/fatigue, major depressive disorders, abnormal gait, anxiety, and burning/numbness (Figure 4)
- Other comorbidities were reported by 63.6% in the nrSPMS cohort and 60.6% in the matched controls ( $P = 0.213$ ); autoimmune comorbidities were reported by 179% in the nrSPMS cohort and 20.4% in the matched controls ( $P = 0.177$ )

Figure 4: Most frequent MS-related comorbidities in the nrSPMS cohort versus matched controls




Data presented as the percentage of people with nrSPMS. MS, multiple sclerosis; nrSPMS, nonrelapsing secondary progressive multiple sclerosis.

### Healthcare resource utilization and healthcare costs

- The nrSPMS cohort had a higher proportion of people with mortality, hospitalizations, emergency visits, and a significantly higher mean number of physician visits versus matched controls during the follow-up period (Figure 5)
  - The mean (SD) length of hospital stay was 13.8 [22.8] days in the nrSPMS cohort and 12.4 [17.6] days in the matched controls ( $P = 0.630$ )

Figure 5: All-cause HCRU in the nrSPMS cohort versus matched controls




Data presented as the percentage of people with nrSPMS. HCRU, Healthcare Resource Utilization; MS, multiple sclerosis; nrSPMS, nonrelapsing secondary progressive multiple sclerosis.

### References

- Multiple Sclerosis International Federation (MSIF). Atlas of MS. 2023. Accessed February 02, 2024. <https://www.atlasofms.org/fact-sheet/united-states-of-america>.
- Cree BAC, et al. *Neurology*. 2021;97:378–388.
- Weinshenker BG, et al. *Brain*. 1989;112(pt 1):133–146.
- Watson C, et al. *Neural Ther*. 2023;12(6):1961–1979.
- Müller S, et al. *Neural Ther*. 2020;9(1):67–83.
- Campbell JD, et al. *Mult Scler Relat Disord*. 2014;3(2):227–236.
- Greene N, et al. Poster presented at: Academy of Managed Care Pharmacy (AMCP) Nexus, Orlando, October 16–19, 2023; FL, USA.

- The mean total HCCs were significantly higher in the nrSPMS cohort than that in matched controls, which were primarily driven by outpatient pharmacy and physician visit costs (Figure 6)

Figure 6: Healthcare costs in the nrSPMS cohort versus matched controls




Data presented as mean cost. Cost of infections: Costs of medical claims with a diagnosis of infections in any field plus the costs of antibiotics or antivirals pharmacy claims with days of supply <21 days filled within 7 days of an infection medical claim. ED, emergency department; nrSPMS, nonrelapsing secondary progressive multiple sclerosis; US, United States.

### Treatment pattern

- Around 41.1% and 49.8% of people with nrSPMS were treated with a DMT at index and after 1-year follow-up
- The most used DMTs among people with nrSPMS at index and after 1-year follow-up were glatiramer acetate (11.1% and 13.0%), dimethyl fumarate (9.6% and 12.3%), and beta-interferon (8.8% and 9.9%)
- Among the 426 people on a DMT at index, 388 (91.1%) remained on their first observed DMT and 38 switched to a second DMT during the 1-year post-index period; of which 2 switched to a third DMT (Figure 7)

Figure 7: DMT switch pattern, by individual drug among people with nrSPMS using DMT



Data presented as n (%). DMT, disease-modifying therapy; nrSPMS, nonrelapsing secondary progressive multiple sclerosis.

## LIMITATIONS

- This study may have potentially under-represented the proportion of people with nrSPMS treated with DMTs as it does not encompass individuals who may have previously received such treatments
- The random selection of index date and 1 year follow-up may not fully capture the true extent of treatment in this population due to the limited approved treatment options for nrSPMS
- As this study offers a cross-sectional look at the burden of illness for people with nrSPMS, a static perspective may not fully capture the dynamic nature of managing people with nrSPMS over time, including potential treatment discontinuation and lack of consistent treatment due to limited treatment options

## CONCLUSIONS

Overall, people with nrSPMS exhibit a higher prevalence of comorbidities and a substantially increased HCRU compared to matched controls, resulting in additional clinical and economic burden in a population with no approved therapies



Copies of this poster obtained through Quick Response (QR) code are for personal use only